Clinical results show Lecraza monotherapy has a progression-free survival (PFS) of 18.5 months, compared to 16.6 months for Tagrisso, with an objective response rate (ORR) of 83% versus 85%. Yuhan Corporation plans to consult with Johnson & Johnson for FDA approval of Lecraza monotherapy, which could potentially exceed $5 billion in annual sales.